Intuitive Surgical, Inc.

DB:IUI1 Stock Report

Market Cap: €181.7b

Intuitive Surgical Valuation

Is IUI1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IUI1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IUI1 (€514.6) is trading above our estimate of fair value (€326.19)

Significantly Below Fair Value: IUI1 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IUI1?

Key metric: As IUI1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for IUI1. This is calculated by dividing IUI1's market cap by their current earnings.
What is IUI1's PE Ratio?
PE Ratio85.5x
EarningsUS$2.24b
Market CapUS$191.82b

Price to Earnings Ratio vs Peers

How does IUI1's PE Ratio compare to its peers?

The above table shows the PE ratio for IUI1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.9x
SHL Siemens Healthineers
29.4x14.2%€57.0b
AFX Carl Zeiss Meditec
24.8x16.3%€5.0b
EUZ Eckert & Ziegler
26.3x5.2%€943.0m
DRW3 Drägerwerk KGaA
7.2x2.0%€792.5m
IUI1 Intuitive Surgical
85.5x11.5%€191.8b

Price-To-Earnings vs Peers: IUI1 is expensive based on its Price-To-Earnings Ratio (85.5x) compared to the peer average (21.9x).

Price to Earnings Ratio vs Industry

How does IUI1's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
IUI1 85.5xIndustry Avg. 29.8xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: IUI1 is expensive based on its Price-To-Earnings Ratio (85.5x) compared to the European Medical Equipment industry average (29.8x).

Price to Earnings Ratio vs Fair Ratio

What is IUI1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IUI1 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio85.5x
Fair PE Ratio34.7x

Price-To-Earnings vs Fair Ratio: IUI1 is expensive based on its Price-To-Earnings Ratio (85.5x) compared to the estimated Fair Price-To-Earnings Ratio (34.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IUI1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€511.60
€512.02
+0.08%
12.8%€613.74€252.94n/a26
Nov ’25€466.50
€487.74
+4.6%
12.0%€556.16€244.01n/a26
Oct ’25€442.95
€439.46
-0.8%
12.2%€529.39€239.40n/a26
Sep ’25€443.90
€433.68
-2.3%
12.4%€527.22€238.42n/a26
Aug ’25€416.70
€433.63
+4.1%
11.0%€485.05€244.83n/a25
Jul ’25€414.00
€398.85
-3.7%
11.2%€467.60€236.61n/a25
Jun ’25€374.10
€391.12
+4.5%
11.0%€461.70€233.62n/a25
May ’25€348.15
€392.29
+12.7%
10.5%€443.03€235.97n/a25
Apr ’25€369.10
€383.88
+4.0%
10.5%€440.33€234.53n/a25
Mar ’25€364.45
€378.35
+3.8%
12.1%€439.99€213.05n/a25
Feb ’25€351.75
€372.74
+6.0%
13.9%€439.61€212.87n/a25
Jan ’25€306.95
€306.47
-0.2%
13.2%€363.56€209.05n/a25
Dec ’24€287.15
€299.32
+4.2%
12.7%€366.56€210.77n/a25
Nov ’24€254.45
€307.00
+20.7%
12.8%€377.96€217.33€466.5024
Oct ’24€275.95
€326.23
+18.2%
10.5%€360.56€207.32€442.9523
Sep ’24€287.50
€326.23
+13.5%
10.5%€360.56€207.32€443.9023
Aug ’24€294.60
€326.23
+10.7%
10.5%€360.56€207.32€416.7023
Jul ’24€313.00
€286.76
-8.4%
10.5%€337.11€188.41€414.0021
Jun ’24€288.20
€287.26
-0.3%
10.1%€340.22€190.15€374.1021
May ’24€272.05
€277.00
+1.8%
9.6%€317.63€185.13€348.1521
Apr ’24€234.80
€250.44
+6.7%
11.5%€299.81€188.19€369.1021
Mar ’24€213.05
€251.43
+18.0%
12.3%€298.45€187.33€364.4520
Feb ’24€228.95
€251.43
+9.8%
12.3%€298.45€187.33€351.7520
Jan ’24€247.80
€255.27
+3.0%
14.7%€306.09€192.13€306.9521
Dec ’23€257.70
€252.10
-2.2%
13.8%€314.76€197.57€287.1520
Nov ’23€250.70
€253.18
+1.0%
12.4%€326.14€204.71€254.4520

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.6b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

-0.9%

1Y

-35.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%

OrbusNeich Medical Group Holdings

HK$3.1b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

Q8T

HK$0.40

7D

-21.2%

1Y

-46.9%